Schedule-dependent interactions between paclitaxel and etoposide in human carcinoma cell lines in vitro.
Clinical studies of paclitaxel in combination with etoposide against solid tumors have been carried out. The combination schedules used in these studies are different. We studied the cytotoxic effects of paclitaxel with etoposide against four human cancer cell lines in vitro to determine the optimal schedule of this combination at the cellular level. Cells were exposed simultaneously to paclitaxel and to etoposide for 24 h or sequentially to one drug for 24 h followed by the other for 24 h, after which they were incubated in drug-free medium for 4 and 3 days, respectively. Cell growth inhibition was determined by an MTT reduction assay. The effects of drug combinations at concentrations producing 80% inhibition (IC(80)) were analyzed by the isobologram method of Steel and Peckham. The cytotoxic effect of paclitaxel and etoposide was cell line- and schedule-dependent. Simultaneous exposure to paclitaxel and etoposide for 24 h produced additive effects in the lung cancer cell line A549 and ovarian cancer PA1 cells, and antagonistic effects in the breast cancer cell line MCF7 and colon cancer WIDr cells. Sequential exposures to paclitaxel followed by etoposide and vice versa produced additive effects in all four cell lines. These results suggest that maximum cytotoxic effects can be obtained with sequential administration, but not simultaneous administration, of paclitaxel and etoposide. These findings may have important clinical implications for this combination.
Kano
Y
Y
Division of Medical Oncology, Tochigi Cancer Center, Yonan, 4-9-13, Utsunomiya, Tochigi, 320-0834, Japan. ykano@tcc.pref.tochigi.jp
Akutsu
M
M
Suzuki
K
K
Mori
K
K
Yazawa
Y
Y
Tsunoda
S
S
D001943:Breast Neoplasms; D002289:Carcinoma, Non-Small-Cell Lung; D002455:Cell Division / Q000187:drug effects; D003110:Colonic Neoplasms; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004354:Drug Screening Assays, Antitumor; D005047:Etoposide / Q000633:toxicity*; D005260:Female; D006801:Humans; D008175:Lung Neoplasms; D010051:Ovarian Neoplasms; D017239:Paclitaxel / Q000633:toxicity*; D013997:Time Factors; D014407:Tumor Cells, Cultured
D005047:Etoposide; D017239:Paclitaxel